Corvus Pharmaceuticals (CRVS) Stock Forecast, Price Target & Predictions
CRVS Stock Forecast
Corvus Pharmaceuticals stock forecast is as follows: an average price target of $7.00 (represents a 37.25% upside from CRVS’s last price of $5.10) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
CRVS Price Target
The average price target for Corvus Pharmaceuticals (CRVS) is $7.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 37.25% upside from CRVS's last price of $5.10.
CRVS Analyst Ratings
According to 1 Wall Street analysts, Corvus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CRVS stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Corvus Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 18, 2023 | Jeff Jones | Oppenheimer | $7.00 | $2.19 | 219.65% | 37.25% |
The latest Corvus Pharmaceuticals stock forecast, released on Aug 18, 2023 by Jeff Jones from Oppenheimer, set a price target of $7.00, which represents a 219.65% increase from the stock price at the time of the forecast ($2.19), and a 37.25% increase from CRVS last price ($5.10).
Corvus Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $5.10 | $5.10 | $5.10 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Corvus Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Corvus Pharmaceuticals's last price of $5.10. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 07, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 18, 2023 | Oppenheimer | - | Outperform | Initialise |
Corvus Pharmaceuticals's last stock rating was published by Oppenheimer on May 07, 2024. The company gave CRVS a "Outperform" rating, the same as its previous rate.
Corvus Pharmaceuticals Financial Forecast
Corvus Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Corvus Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CRVS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Corvus Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict CRVS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Corvus Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Corvus Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-8.96M | $-8.96M | $-8.36M | $-8.36M | $-6.72M | $-6.57M | $-6.87M |
| High Forecast | $-8.96M | $-8.96M | $-8.36M | $-8.36M | $-6.72M | $-5.97M | $-6.87M |
| Low Forecast | $-8.96M | $-8.96M | $-8.36M | $-8.36M | $-6.72M | $-6.57M | $-6.87M |
| Surprise % | - | - | - | - | - | - | - |
Corvus Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CRVS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Corvus Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Corvus Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CRVS last annual SG&A of $NaN (undefined).
Corvus Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.11 | $-0.11 | $-0.12 |
| High Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.11 | $-0.10 | $-0.12 |
| Low Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.14 | $-0.11 | $-0.11 | $-0.12 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Corvus Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CRVS previous annual EPS of $NaN (undefined).
Corvus Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| CRVS | Corvus Pharmaceuticals | $5.10 | $7.00 | 37.25% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
CRVS Forecast FAQ
Is Corvus Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Corvus Pharmaceuticals (CRVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CRVS's total ratings.
What is CRVS's price target?
Corvus Pharmaceuticals (CRVS) average price target is $7 with a range of $7 to $7, implying a 37.25% from its last price of $5.1. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Corvus Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for CRVS stock, the company can go up by 37.25% (from the last price of $5.1 to the average price target of $7), up by 37.25% based on the highest stock price target, and up by 37.25% based on the lowest stock price target.
Can Corvus Pharmaceuticals stock reach $8?
CRVS's average twelve months analyst stock price target of $7 does not support the claim that Corvus Pharmaceuticals can reach $8 in the near future.
What are Corvus Pharmaceuticals's analysts' financial forecasts?
Corvus Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-20.152M (high $-19.555M, low $-20.152M), average SG&A $0 (high $0, low $0), and average EPS is $-0.338 (high $-0.328, low $-0.338). CRVS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-34.632M (high $-34.632M, low $-34.632M), average SG&A $0 (high $0, low $0), and average EPS is $-0.58 (high $-0.58, low $-0.58).